This webinar explores a highly sensitive, automated assay workflow to provide high-quality results for low-abundance biomarkers in serum, plasma and cerebrospinal fluid.

Driving biomarker discovery is key as proteomics emerges as the next frontier in precision medicine.
In this webinar, you’ll hear how proteomics technology can enhance the identification of biomarkers for the accurate diagnosis of Crohn’s disease and ulcerative colitis, as well as the identification of biomarkers that predict response to TNF inhibitors and other biologics in patients with IBD.
This webinar will explore how reliable, non-invasive proteomic biomarkers are pivotal for personalized treatment and increasing our knowledge of biological pathways involved in disease. Our expert speaker will also present an assay platform that can measure 11,000 biologically relevant proteins in the search for biomarkers.

Join this webinar to learn the fundamentals of spatial multiplexing for single-cell proteomics and hear how it enables the in-depth exploration of complex tissue microenvironments through the detection and quantification of a virtually unlimited number of protein target analytes.

Meaningful biomarker studies that account for genetic, environmental and lifestyle variation, or comprise of complex signatures from multiple proteins, require large cohorts – too large for the current proteomics discovery platforms.

Alzheimer’s disease (AD) is the most common form of dementia in the elderly population. While several peptide and protein biomarkers in cerebrospinal fluid (CSF) have been used for AD diagnosis, an unequivocal diagnosis in the early phases of AD is still lacking.

To ensure the safety and efficacy of LNP-based drugs, comprehensive characterization of these sophisticated molecules–the lipids and the genetic cargo–is paramount.